Mechanisms and applications of hypertonic saline

Journal of the Royal Society of Medicine, Supplement

Volumn 104, Issue SUPPL. 1, 2011, Pages

  Elkins, Mark R ^a   Bye, Peter T P ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHLORIDE ION; DNA; DORNASE ALFA; EPITHELIAL SODIUM CHANNEL; GLUTATHIONE; HYALURONIC ACID; MUCOLYTIC AGENT; MUCOPROTEIN; SODIUM CHLORIDE; SODIUM ION; THIOCYANATE; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRULENCE FACTOR;

ARTICLE; BIOFILM; BRONCHIECTASIS; CHEMICAL BOND; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GEL; HUMAN; LONG TERM CARE; LUNG DISEASE; LUNG FUNCTION; MUCOLYSIS; NONHUMAN; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PSEUDOMONAS AERUGINOSA; PULSE OXIMETRY; SPIROMETRY; SPUTUM ANALYSIS; SYMPTOM; TREATMENT OUTCOME; VISCOELASTICITY; REVIEW;

CYSTIC FIBROSIS; HUMANS; SALINE SOLUTION, HYPERTONIC;

EID: 80052615746     PISSN: 02675331     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.2011.s11101     Document Type: Article

References (29)

1. Rubin BK. Taxonomy of mucoactive medications. In: Rubin BK, van der Schans CP, eds. Therapy for Mucus-Clearance Disorders. Volume 188, Lung Biology in Health and Disease. New York, NY: Marcel Dekker, 2004:129-45
2. Henke M, Ratjen F. Mucolytics in cystic fibrosis. Paed Respir Rev 2007;8:24-9
3. Ziment I. Respiratory Pharmacology and Therapeutics. Philadelphia, PA: WB Saunders, 1978:60-104
4. Scheffner AL, Medler EM, Jacobs LW, Sarett HP. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964;90:721-9
5. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997;156:173-7
6. Wills PJ, Cole PJ. Sodium chloride improves ciliary transportability of sputum. Am J Respir Crit Care Med 1995;151:A720
7. Wills PJ, Hall RL, Chan WM, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997;99:9-13
8. Lieberman J, Kurnick NB. Influence of deoxyribonucleic acid content on the proteolysis of sputum and pus. Nature 1962;196:988-90
9. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50
10. Tarran R, Grubb BR, Parsons D, et al. The CF Salt Controversy: In Vivo Observations and Therapeutic Approaches. Mol Cell 2001;8:149-58
11. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in Cystic Fibrosis with hypertonic saline. New Engl J Med 2006;354:241-50
12. Goralski J, Button B. In vitro study of the kinetics of hypertonic saline on ASL height. Ped Pulmonol 2010;45: A205
13. Tarran R, Grubb BR, Gatzy JT, Davis CW, Boucher RC. The relative roles of passive surface forces and active ion transport in the modulation of airway surface liquid volume and composition. J Gen Physiol 2001;118:223-36
14. Elkins MR, Bye PTP. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006;12:445-52
15. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9
16. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3
17. Murray TS. The effect of hypertonic saline on in vitro Pseudomonas aeruginosa colonization. Ped Pulmonol 2010;45: A367
18. Gould NS, Gauthier S, Kariya CT, Min E, Huang J, Day BJ. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir Res 2010;11;119
19. de Boeck K, Alifier, Vandeputte S. Sputum induction in young cystic fibrosis patients. Eur Respir J 2000;16: 91-4
20. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56:306-11
21. Kastelik JA, Aziz I, Morice AH. Sputum induction in young cystic fibrosis patients. Eur Respir J 2001;17:1
22. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputuminduction. Am J Respir Crit Care Med 2001;164:1425-31
23. Riedler J, Reade T, Button B, Robertson CF. Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. J Paediatr Child Health 1996;32:48-50
24. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Ped Pulmonol 1996;21:77-83
25. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New Engl J Med 2006;354:229-40
26. Bye PTP, Elkins MR. Other mucoactive agents for cystic fibrosis. Paed Respir Rev 2007;8:30-9
27. Buonpensiero P, De Gregorio F, Sepe A, et al. Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis. Adv Ther 2010;27:870-8
28. King PT. The pathophysiology of bronchiectasis. Int J COPD 2009;4:411-19
29. Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbation indices and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-7